This SR highlights the lack of long-term RCTs reporting final height data and other important qualitative outcomes , such as quality of life .
ABSTRACT Genotropin ( somatropin ) is licensed for the treatment of children with growth hormone deficiency , Prader-Willi syndrome , Turner syndrome , chronic renal insufficiency and in children born small for gestational age .
This systematic review ( SR ) evaluated the clinical efficacy and effectiveness of Genotropin in these conditions to inform a NICE Technology Appraisal of growth hormone for the treatment of growth failure in children .
Response to Growth Hormone with Respect to Pubertal Status on Increased Dose in Idiopathic Growth Hormone Deficiency: An Analysis of Turkish Children in the KIGS Database (Pfizer International Growth Study)
AIM To compare the growth response to growth hormone ( GH ) treatment in patients with idiopathic GH deficiency ( IGHD ) who were prepubertal with the response of those who were pubertal at the onset of GH therapy on an increased GH dose . PATIENTS AND METHODS Among the Turkish patients enrolled in the Pfizer International Growth Study ( KIGS ) data base with the diagnosis of IGHD , the growth data over 2 years of GH therapy were analyzed longitudinally of 113 ( 79 M ) prepubertal ( Group 1 ) and 44 ( 33 M ) pubertal ( Group 2 ) patients .  Pubertal signs were reported to be present initially or to have appeared within 6 months of GH therapy in Group 2 . Mean + /- SD age at onset of therapy was 8.7 + /- 3.5 and 13.5 + /- 1.8 years ; height SDS -4.2 + /- 1.4 and -3.2 + /- 1.1 ( p < 0.05 ) in Groups 1 and 2 , respectively . Mid-parental height ( MPH ) SDS did not show a significant difference between the two groups ( -1.5 + /- 1.1 vs -1.7 + /- 1.1 ) . RESULTS Delta height SDS over 2 years of therapy was significantly higher in Group 1 ( 1.1 + /- 1.0 ) than in Group 2 ( 0.7 + /- 0.6 ) ( p < 0.05 ) in spite of a significantly lower dose of GH ( 14.6 + /- 3.3 in Group 1 vs 17.0 + /- 3.1 IU/m2/week in Group 2 , p < 0.05 ) . Ht -- MPH SDS showed an increase from -2.4 + /- 1.7 to -1.4 + /- 1.5 in Group 1 and from -1.5 + /- 1.5 to -0.8 + /- 1.3 in Group 2 . Overall delta height SDS showed negative correlations with age ( r = -0.32 ) , height SDS ( r = -0.41 ) and height -- MPH SDS ( r = -0.40 ) at onset of therapy ( p < 0.001 ) . CONCLUSIONS These data show that in IGHD the slight increase ( 15 - 20 % ) in the dose of GH during puberty was not adequate to maintain height velocity at the same magnitude as in prepuberty , and thus was not cost effective
This SR highlights the lack of long-term RCTs reporting final height data and other important qualitative outcomes , such as quality of life .
ABSTRACT Genotropin ( somatropin ) is licensed for the treatment of children with growth hormone deficiency , Prader-Willi syndrome , Turner syndrome , chronic renal insufficiency and in children born small for gestational age .
This systematic review ( SR ) evaluated the clinical efficacy and effectiveness of Genotropin in these conditions to inform a NICE Technology Appraisal of growth hormone for the treatment of growth failure in children .